Previous MEK inhibitor studies recommended ocular screening of patients based on incidences of ocular adverse events observed; some ocular adverse events, such as conjunctivitis, were detected as part of routine physical examination of patients, while others, including retinopathy, required ophthalmologic examination.17 A baseline ophthalmologic evaluation, including visual acuity and fundoscopy, may be useful for all patients initiating MEK inhibitor therapy.17 A baseline exam will allow differentiation of preexisting pathology from MEKAR. The gene discussed is MAP2K7; the disease is conjunctivitis.